NIB Holdings Limited vs Medibank Private Ltd: Which is the better buy?

Is NIB Holdings Limited (ASX:NHF) or Medibank Private Ltd (ASX:MPL) the better buy at current prices?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The private health insurance sector is becoming more competitive and with the number of comparison sites seemingly increasing every year, switching health insurers is becoming increasingly simple.

Against this backdrop, Australia's two listed private health insurers, NIB Holdings Limited (ASX: NHF) and Medibank Private Ltd (ASX: MPL) have experienced a mixed 12 months with the share prices of both companies lacking any significant direction.

Here is a head to head comparison of some of the most important aspects from their FY15 results:

Premium Revenue

NIB: 9.6% increase  vs Medibank: 3.3% increase

NIB is the clear winner in premium growth with Medibank suffering from increased membership lapses and fewer sales from higher value policies. Interestingly, NIB surpassed 1 million Australian customers for the first time in FY15.

Gross Underwriting Margin

NIB: 16.4% vs Medibank: 14.2%

NIB is again the winner here with the company keeping a higher share of its premiums after claims have been paid out.

Operating Margin

NIB: 4.9% vs Medibank: 5.5%

After taking out other expenses, Medibank is the winner here. The graph below shows the operating margins of the top six private health insurers in Australia and it is interesting to note the opposing trends of NIB and Medibank over the last three years.

CaptureSource: Medibank FY15 Presentation

With Medibank's much larger size and scale, it would be expected that its operating margins would be higher than NIB and with further cost saving measures still to be implemented, Medibank's operating margin should continue to increase over the next few years. Interestingly, Medibank has been able to increase its operating margin significantly since FY14 when it was only 4.4%.

Policyholder Growth

NIB: 4.7% increase vs Medibank: 0.9% increase

NIB is the standout winner in policyholder growth, with the company growing policyholder numbers well above the industry average of 2.5%. Medibank on the other hand delivered disappointing growth in this area with the company blaming challenging industry conditions and slowing market growth for its below average growth.

Claims Expense Growth

NIB: 7.5% vs Medibank: 3.4%

Medibank is the clear winner when it comes to managing the rising costs involved with medical care. Both companies are under pressure to deal with healthcare costs that are increasing faster than inflation and faster than either company can implement increases to customers through higher premiums. NIB's claims expense growth in FY15 is concerning as it is by far the highest it has been over the last five years and appears to be trending in the wrong direction. NIB's gross underwriting margin will come under significant pressure unless the company can get claims inflation under control.

Return on Investments

NIB: 4.8% (excludes the benefits from the sale of its stake in Pacific Smiles Group (ASX: PSQ))  vs Medibank: 4.4%

Both companies produced a similar return from their investment portfolios. It is interesting to note that Medibank has 25% of its investment portfolio allocated to growth assets compared to NIB which has 17% allocated to growth.

Current Valuation

NIB: 17.5 x FY15 earnings vs Medibank: 21x FY15 earnings

Dividend Yield (FY16 Forecast)

NIB: 4.0% vs Medibank: 3.7%

Foolish takeaway

It's clear each company has its own positives and negatives and in my mind there is no standout winner. If I had to choose one company for exposure to this sector however, it would have to be NIB. Its policyholder growth is far superior to Medibank and its current valuation is also more attractive for a long-term investment.

FY16 will be an interesting year for both stocks and although both companies have provided positive earnings guidance for the year ahead, there are a number of challenges in the short term that could impact on margins moving forward.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »